Clinical trials: Busulfan
Severe Combined Immunodeficiency
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe combined immune deficiency (SCID) may result from inherited deficiency of the enzyme adenosine deaminase (ADA). Children with ADA-deficient SCID often die from infections in infancy, unless treated with either a bone…
- Trial name
- NCT00794508
- Testing
- ADA gene transfer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Donald B. Kohn, M.D.
MDS, Leukemias
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
The purpose of this study is to see if giving high dose chemotherapy and total body irradiation before and repeating high dose chemotherapy after a bone marrow transplant could reduce the incidence of graft rejection and disease…
- Conditions
- MDS, Leukemias, Lymphomas
- Trial name
- NCT00796562
- Testing
- Busulfan, Cyclophosphamide, Total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Chronic Myelogenous Leukemia
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML.
- Trial name
- NCT01390402
- Testing
- Fludarabine, Busulfan, NK cell infusion:
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Plasma Cell Leukemia, Plasmacytoma
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or…
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT02506959
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Myeloproliferative Diseases
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
The goal of this clinical research study is to learn if giving pacritinib before standard of care drugs followed by an allogeneic stem cell transplant can help to control myeloproliferative neoplasms.
- Trial name
- NCT02410551
- Testing
- Pacritinib, Busulfan, Questionnaires
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Leukemia
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant or peripheral stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00611351
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01605032
- Testing
- Busulfan, Melphalan, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Albert Einstein College of Medicine
Acute Myeloblastic Leukemia
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
Although transplant results for AML in complete remission (CR) at the time of transplant have improved, transplant results for non-remission AML have been quite poor.
- Trial name
- CloBu4 (NCT01457885)
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant
- Where
- 12 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782379
- Testing
- busulfan, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML)
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
- Conditions
- Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma
- Trial name
- NCT03615105
- Testing
- Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sickle Cell Disease, Thalassemia
A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen
Hypothesis 1: A novel nonmyeloablative condition regimen will be safe and efficacious in producing stable donor chimerism and cure of severe hemoglobinopathy.
- Conditions
- Sickle Cell Disease, Thalassemia, Hemoglobinopathies
- Trial name
- NCT00427661
- Testing
- Busulfan; Fludarabine; cyclosporine A and MMF
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pittsburgh
Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
T-Cell Depleted Double UCB for Refractory AML
This trial is proposes to build on our experience and is designed to maximize early (day 3-14) and late (day 60-71) donor-derived natural killer (NK) cell expansion and function in vivo.
- Trial name
- NCT01464359
- Testing
- Allopurinol, Fludarabine, Total body irradiation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Fanconi Anemia
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy.
- Trial name
- NCT00258427
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT01823198
- Testing
- Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center